Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

A Case of Capmatinib used in MET Amplification Glioblastoma
Neuro-oncology
P9 - Poster Session 9 (5:30 PM-6:30 PM)
11-001
We present a patient diagnosed with MET amplification (copy number 138.0) positive glioblastoma. The patient underwent surgical resection, radiation, and Temozolomide and repeat imaging showed tumor progression. He was then started on the Optune device. He was subsequently treated with Lomustine, however, imaging showed progression of disease. The patient received Bevacizumab for 2 months. Capmatinib was then started and subsequent imaging showed improvement in enhancement and decrease in associated edema. Capmatinib is a MET inhibitor known to cross the blood brain barrier, used primarily for treatment in non-small cell lung cancer. The patient has survived more than 38 months and underwent a period of 11 months with progression free survival when treated with Capmatinib.
Glioblastoma is an aggressive brain cancer with very few successful treatment options. The standard of care for treatment includes surgical resection, chemotherapy, and radiation. Temozolomide and Bevacizumab are approved chemotherapy regimens for glioblastoma. Gene sequencing has become a more frequently utilized tool to help tailor treatment. 
NA
NA
This patient is unique because he was found to have MET amplification (copy number 138.0) and showed a positive response both clinically and radiographically with a medication not yet regularly studied in glioblastoma. This shows the importance of gene sequencing tumor cells to help guide treatment plans. Capmatinib likely contributed to the positive response in this patient diagnosed with glioblastoma, the most aggressive primary brain tumor.
Authors/Disclosures
Catherine Boldig, DO
PRESENTER
Dr. Boldig has nothing to disclose.
Sepideh Mokhtari, MD (Moffitt Cancer Center) Dr. Mokhtari has nothing to disclose.